The global cell line development market was estimated at $2.67 billion in 2015 and is anticipated to grow at a CAGR of 12.9% from 2022 to reach $6.24 billion. Increasing demand for monoclonal antibodies and patent expirations of blockbuster biologics are expected to drive market growth. North America was the largest market in 2014 due to factors such as adoption of cell culture techniques, supportive government initiatives, and high healthcare spending. Asia Pacific is anticipated to register rapid growth over the forecast period due to presence of CROs, growing R&D investments, and increasing biologics production.

1. FollowUs:
Cell Line Development Market Future Growth Analysis And Forecast To
2022| Grand View Research, Inc
Global cell line development market size is expectedto reach USD 6.24 billionby 2022, according to a newreport by
Grand ViewResearch, Inc. The Increasing demand for monoclonal antibodiesand patent expirationof blockbuster
biologicsare expectedto drive the cell line developmentindustryover the forecast period.
Increasing prevalence of autoimmune diseasesand cancer are likelyto increase the demand for accurate and cost
effective treatment optionswhich is expectedto render a positive impact on market growth. In addition,improving
healthcare infrastructure, economic developmentand favorable government initiativespromoting the growth of the
biotechnologyindustry are factors contributing towards the growth of the cell line developmentmarket.
Ongoing R&D for stable & authentic cell linesand the introduction of technologicallyadvanced processes such as
single use bioreactor and micro bioreactor for large scale bioproductionare further expectedto provide this market
with lucrative future growth opportunities.
Browse Details of Report @ www.grandviewresearch.com/industry-analysis/cell-line-development-market
“The globalcelllinedevelopmentmarketsizewasestimatedat USD 2.67billion
in 2015andisanticipatedtogrowata CAGRof 12.9%overtheforecastperiod.”

2. FollowUs:
Further key findings from the study suggest:
 Reagent and mediawas the largest product market in 2014, owing to increasing number of cell culture
procedures. Reagent and mediaare necessary components involvedin cell line developmentprocedures&
cell culture and are cost intensive innature. The market for reagent and mediawas valuedat over 1.0 billion
in 2014.
 Mammalian cell lineswere widelyusedas a source for cell line developmentin2014, owing to associated
advantages such as accurate complex protein expressionnature, critical for the production of monoclonal
antibodies,vaccines, and biologics.
 Cell line developmentfindsthe largest application in the bioproduction of biologics,vaccines, Mabs,
therapeutic proteins and biosimilars.Rising demand for monoclonal antibodiesand vaccines are expectedto
boost the growth of this segment over the forecast period. The market for cell line developmentbased
bioproduction is also expectedto witnesslucrative growth of over 12.5% during the forecast period.
 North America was the largest market in 2014, with revenue estimatedat over 800 million.The region’s
market dominance is attributed to factors such as the growing adoption rates of cell culture techniques,
presence of well developedhealthcare infrastructure, supportive governmentinitiativesand high healthcare
expenditure levels.
 Asia Pacific cell line developmentmarketis anticipated to register rapid growth over the forecast period
owing to factors such as the presence of high unmet needs, risingnumber of CROs (Contract Research
Organization) providing pertinentservices,growing R&D investmentsaimedat the developmentof stable cell
linesand increasing biologicsproduction.
 Key players inthis market include European Collectionof cell Cultures(ECACC), Lonza Group AG, GE
Healthcare, Thermo Fisher ScientificInc., Sartorious AG, SelexisSA,Wuxi AppTec Inc., Sigma-Aldrich
Corporation, American Type Culture Collection(ATCC) and Corning Inc.
Grand ViewResearch has segmentedthe global cell line developmentmarketon the basis of product, source, type
of cell line,applicationand region:
Global Cell Line Development Product Outlook (Revenue, USD Million, 2012 - 2022)
o Reagents and media
o Equipment Accessoriesand consumables
o Incubators
o Centrifuges
o Bioreactors
o Storage equipment
o Microscopes
Global Cell Line Development Source Outlook (Revenue, USD Million, 2012 - 2022)
o Mammalian
o Non mammalian

3. FollowUs:
o Insects
o Amphibians
Global Cell Line Development Type Of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
o Recombinant cell lines
o Hybridomas
o Continuous cell line
o Primary cell lines
Global Cell Line Development Application Outlook (Revenue, USD Million, 2012 - 2022)
o Bioproduction
o Drug discovery
o Toxicity testing
o Tissue engineering
o Research
Cell Line Development Regional Outlook (Revenue,USD Billion, 2014 - 2022)
o North America
o U.S.
o Canada
o Europe
o Germany
o UK
o Asia Pacific
o China
o Japan
o India
o Latin America
o Mexico
o Brazil
o MEA
o South Africa
Browse Related Category Reports @ www.grandviewresearch.com/industry/biotechnology

4. FollowUs:
Table of Content of Cell Line Development Market
Chapter 1. Methodologyand Scope
1.1. Researchmethodology
1.2. Researchscope &assumption
1.3. Listof data sources
Chapter 2. Executive Summary
2.1. Cell Line Development - IndustrySnapshotandKeyBuyingCriteria,2012 - 2022
Chapter 3. Cell Line DevelopmentIndustryOutlook
3.1. Cell line developmentmarket segmentation
3.2. Cell line developmentmarketsize andgrowthprospects,2012 - 2022
3.3. Cell line developmentmarketdynamics
3.3.1. Market driveranalysis
3.3.2. Market restraintanalysis
3.4. Keyopportunitiesprioritized
3.5. IndustryAnalysis - Porter's
3.6. Cell line developmentcompetitive landscape,2014
3.6.1. Companymarketshare analysis,2014
3.6.2. Market positionanalysis,2014 (basedonproducts,regional presence,andstrategicinitiatives)
3.7. Cell line developmentmarketPESTELanalysis,2014
Chapter 4. Cell Line Development ProductOutlook
4.1. Cell line developmentmarketshare byproduct,2014 & 2022
4.2. Reagentsandmedia
4.2.1. Reagentsandmediamarketestimatesandforecasts,2012 - 2022 (USD million)
4.3. Equipment
4.3.1. Equipmentmarketestimatesandforecasts,2012 - 2022 (USD million)
4.3.2. Incubators
4.3.2.1. Incubatorsmarketestimatesandforecasts,2012 - 2022 (USD million)
4.3.3. Centrifuges
4.3.3.1. Centrifugesmarketestimatesandforecasts,2012 - 2022 (USD million)
4.3.4. Bioreactors
4.3.4.1. Bioreactorsmarketestimatesandforecasts,2012 - 2022 (USD million)
4.3.5. Storage equipment

5. FollowUs:
4.3.5.1. Storage equipmentmarketestimatesandforecasts,2012 - 2022 (USD million)
4.3.6. Microscopes
4.3.6.1. Microscopesmarketestimatesandforecasts,2012 - 2022 (USD million)
4.4. Accessoriesandconsumables
4.4.1. Accessoriesandconsumablesmarketestimatesandforecasts,2012 - 2022 (USD million)
Chapter 5. Cell Line DevelopmentSource Outlook
5.1. Cell line developmentmarketshare bysource,2014 & 2022
5.2. Mammalian
5.2.1. Mammalianmarketestimatesandforecasts,2012 - 2022 (USD million)
5.3. Non-mammalian
5.3.1. Non-mammalianmarketestimatesandforecasts,2012 - 2022 (USD million)
5.3.2. Insects
5.3.2.1. Insectsmarketestimatesandforecasts,2012 - 2022 (USD million)
5.3.3. Amphibians
5.3.3.1. Amphibiansmarketestimatesandforecasts,2012 - 2022 (USD million)
Chapter 6. Cell Line Development Type ofCell LinesOutlook
6.1. Cell line developmentmarketshare,bytype of cell lines,2014 & 2022
6.2. Recombinantcell lines
6.2.1. Recombinantcell linesmarketestimatesandforecasts, 2012 - 2022 (USD million)
6.3. Hybridomas
6.3.1. Hybridomasmarketestimatesandforecasts,2012 - 2022 (USD million)
6.4. Continuouscell lines
6.4.1. Continuouscell linesmarketestimatesandforecasts,2012 - 2022 (USD million)
6.5. Primarycell lines
6.5.1. Primarycell linesmarketestimatesandforecasts,2012 - 2022 (USD million)
Chapter 7. Cell Line DevelopmentApplicationOutlook
7.1. Cell line developmentmarketshare,byapplication,2014 & 2022
7.2. Bioproduction
7.2.1. Bioproductionmarketestimatesandforecasts,2012 - 2022 (USD million)
7.3. Drug discovery
7.3.1. Drug discoverymarketestimatesandforecasts,2012 - 2022 (USD million)
7.4. Toxicitytesting

6. FollowUs:
7.4.1. Toxicitytestingmarketestimatesandforecasts,2012 - 2022 (USD million)
7.5. Vaccines
7.5.1. Vaccinesmarketestimatesandforecasts,2012 - 2022 (USD million)
7.6. Tissue engineering
7.6.1. Tissue engineeringmarketestimatesandforecasts,2012 - 2022 (USD million)
7.7. Others
7.7.1. Othersmarketestimatesandforecasts,2012 - 2022 (USDmillion)
Chapter 8. Cell Line DevelopmentRegional Outlook
8.1. Cell line developmentmarketshare,byregion,2014 & 2022
8.2. NorthAmerica
8.2.1. North Americacell line developmentmarketestimatesandforecasts,byproduct,2012 - 2022 (USD
million)
8.2.1.1. U.S.
8.2.1.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.2.1.2. Canada
8.2.1.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.2.2. North Americacell line developmentmarketestimatesandforecasts,bysource,2012 - 2022 (USD
million)
8.2.2.1. U.S.
8.2.2.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.2.2.2. Canada
8.2.2.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.2.3. North Americacell line developmentmarketestimatesandforecasts,bytype of cell lines,2012 -
2022 (USD million)
8.2.3.1. U.S.
8.2.3.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.2.3.2. Canada
8.2.3.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.2.4. North Americacell line developmentmarketestimatesandforecasts,byapplication,2012 - 2022
(USD million)
8.2.4.1. U.S.
8.2.4.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022

7. FollowUs:
8.2.4.2. Canada
8.2.4.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.3. Europe
8.3.1. Europe cell line developmentmarketestimatesandforecasts,byproduct,2012 - 2022 (USD million)
8.3.1.1. UK
8.3.1.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.3.1.2. Germany
8.3.1.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.3.2. Europe cell line developmentmarketestimatesandforecasts,bysource,2012 - 2022 (USD million)
8.3.2.1. UK
8.3.2.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.3.2.2. Germany
8.3.2.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.3.3. Europe cell line developmentmarketestimatesandforecasts,bytype of cell lines,2012 - 2022 (USD
million)
8.3.3.1. UK
8.3.3.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.3.3.2. Germany
8.3.3.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.3.4. Europe cell line developmentmarketestimatesandforecasts,byapplication,2012 - 2022 (USD
million)
8.3.4.1. UK
8.3.4.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.3.4.2. Germany
8.3.4.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.4. AsiaPacific
8.4.1. AsiaPacificcell line developmentmarketestimatesandforecasts,byproduct,2012 - 2022 (USD
million)
8.4.1.1. Japan
8.4.1.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.4.1.2. China
8.4.1.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022

8. FollowUs:
8.4.1.3. India
8.4.1.3.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.4.2. AsiaPacificcell line developmentmarketestimatesandforecasts,bysource,2012 - 2022 (USD
million)
8.4.2.1. Japan
8.4.2.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.4.2.2. China
8.4.2.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.4.2.3. India
8.4.2.3.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.4.3. AsiaPacificcell line developmentmarketestimatesandforecasts,bytype of cell lines,2012 - 2022
(USD million)
8.4.3.1. Japan
8.4.3.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.4.3.2. China
8.4.3.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.4.3.3. India
8.4.3.3.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.4.4. AsiaPacificcell line developmentmarketestimatesandforecasts,byapplication,2012 - 2022 (USD
million)
8.4.4.1. Japan
8.4.4.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.4.4.2. China
8.4.4.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.4.4.3. India
8.4.4.3.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.5. LatinAmerica
8.5.1. Latin Americacell line developmentmarketestimatesandforecasts,byproduct,2012 - 2022 (USD
million)
8.5.1.1. Mexico
8.5.1.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.5.1.2. Brazil

9. FollowUs:
8.5.1.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.5.2. Latin Americacell line developmentmarketestimatesandforecasts,bysource,2012 - 2022 (USD
million)
8.5.2.1. Mexico
8.5.2.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.5.2.2. Brazil
8.5.2.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.5.3. Latin Americacell line developmentmarketestimatesandforecasts,bytype of cell lines,2012 - 2022
(USD million)
8.5.3.1. Mexico
8.5.3.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.5.3.2. Brazil
8.5.3.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.5.4. Latin Americacell line developmentmarketestimatesandforecasts,byapplication,2012 - 2022
(USD million)
8.5.4.1. Mexico
8.5.4.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.5.4.2. Brazil
8.5.4.2.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.6. MEA
8.6.1. MEA cell line developmentmarketestimatesandforecasts,byproduct,2012 - 2022 (USD million)
8.6.1.1. SouthAfrica
8.6.1.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.6.2. MEA cell line developmentmarketestimatesandforecasts,bysource,2012 - 2022 (USD million)
8.6.2.1. SouthAfrica
8.6.2.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.6.3. MEA cell line developmentmarketestimatesandforecasts,bytype of cell lines,2012 - 2022 (USD
million)
8.6.3.1. SouthAfrica
8.6.3.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
8.6.4. MEA cell line developmentmarketestimatesandforecasts, byapplication,2012 - 2022 (USD million)
8.6.4.1. SouthAfrica

10. FollowUs:
8.6.4.1.1. Cell line developmentmarketestimatesandforecasts,2012 - 2022
Chapter 9. Competitive Landscape
9.1. General ElectricCompany(GEHealthcare)
9.1.1. CompanyOverview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. StrategicInitiatives
9.2. ThermoFisherScientificInc.
9.2.1. CompanyOverview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. StrategicInitiatives
9.3. PublicHealthEngland(EuropeanCollectionof CellCultures)
9.3.1. CompanyOverview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. StrategicInitiatives
9.4. Lonza
9.4.1. CompanyOverview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. StrategicInitiatives
9.5. Sigma-AldrichCo.
9.5.1. CompanyOverview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. StrategicInitiatives
9.6. WuXi AppTec
9.6.1. CompanyOverview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. StrategicInitiatives

11. FollowUs:
9.7. ATCC(AmericanType Culture Collection)
9.7.1. CompanyOverview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. StrategicInitiatives
9.8. SartoriusAG
9.8.1. CompanyOverview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. StrategicInitiatives
9.9. CorningIncorporated
9.9.1. CompanyOverview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. StrategicInitiatives
9.10. Selexis
9.10.1. CompanyOverview
9.10.2. Financial Performance
9.10.3. ProductBenchmarking
9.10.4. StrategicInitiatives
9.11. VistaBiologicalsCorporation
9.11.1. CompanyOverview
9.11.2. Financial Performance
9.11.3. ProductBenchmarking
9.11.4. StrategicInitiatives
9.12. EubiologicsCO.,LTD.
9.12.1. CompanyOverview
9.12.2. Financial Performance
9.12.3. ProductBenchmarking
9.12.4. StrategicInitiatives
9.13. ParagonBioservices,Inc.
9.13.1. CompanyOverview

12. FollowUs:
9.13.2. Financial Performance
9.13.3. ProductBenchmarking
9.13.4. StrategicInitiatives
9.14. Cobra Biologics
9.14.1. CompanyOverview
9.14.2. Financial Performance
9.14.3. ProductBenchmarking
9.14.4. StrategicInitiatives
9.15. GallusBiopharmaceuticals(AcquiredbyPatheon)
9.15.1. CompanyOverview
9.15.2. Financial Performance
9.15.3. ProductBenchmarking
9.15.4. StrategicInitiatives
9.16. SamsungBiologics
9.16.1. CompanyOverview
9.16.2. Financial Performance
9.16.3. ProductBenchmarking
9.16.4. StrategicInitiatives
9.17. Naeja
9.17.1. CompanyOverview
9.17.2. Financial Performance
9.17.3. ProductBenchmarking
9.17.4. StrategicInitiatives
9.18. AragenBioscience
9.18.1. CompanyOverview
9.18.2. Financial Performance
9.18.3. ProductBenchmarking
9.18.4. StrategicInitiatives
9.19. GVK BIO
9.19.1. CompanyOverview
9.19.2. Financial Performance
9.19.3. ProductBenchmarking

13. FollowUs:
9.19.4. StrategicInitiatives
9.20. PCT
9.20.1. CompanyOverview
9.20.2. Financial Performance
9.20.3. ProductBenchmarking
9.20.4. StrategicInitiatives
9.21. Apath
9.21.1. CompanyOverview
9.21.2. Financial Performance
9.21.3. ProductBenchmarking
9.21.4. StrategicInitiatives
9.22. Cell forcure
9.22.1. CompanyOverview
9.22.2. Financial Performance
9.22.3. ProductBenchmarking
9.22.4. StrategicInitiatives
9.23. TRL
9.23.1. CompanyOverview
9.23.2. Financial Performance
9.23.3. ProductBenchmarking
9.23.4. StrategicInitiatives
9.24. Episteme
9.24.1. CompanyOverview
9.24.2. Financial Performance
9.24.3. ProductBenchmarking
9.24.4. StrategicInitiatives
9.25. Catalent
9.25.1. CompanyOverview
9.25.2. Financial Performance
9.25.3. ProductBenchmarking
9.25.4. StrategicInitiatives
9.26. Bioceros

14. FollowUs:
9.26.1. CompanyOverview
9.26.2. Financial Performance
9.26.3. ProductBenchmarking
9.26.4. StrategicInitiatives
9.27. Antitope
9.27.1. CompanyOverview
9.27.2. Financial Performance
9.27.3. ProductBenchmarking
9.27.4. StrategicInitiatives
9.28. Promocell
9.28.1. CompanyOverview
9.28.2. Financial Performance
9.28.3. ProductBenchmarking
9.28.4. StrategicInitiatives
9.29. Cyagen
9.29.1. CompanyOverview
9.29.2. Financial Performance
9.29.3. ProductBenchmarking
9.29.4. StrategicInitiatives

15. FollowUs:
About Us:
Grand ViewResearch, Inc. is a U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To helpclients make informed business decisions, the company offers
market intelligence studiesensuring relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist,USA
Grand ViewResearch, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: http://www.grandviewresearch.com